18:26
Empowering Patient Story and Coya’s Fight Against Neurodegenerative Diseases
00:58
Coya Therapeutics: Commercializing Dr. Appel's Therapy
00:50
Enough Time to Save 500,000 people From ALS & Frontotemporal Dementia (FTD)
01:13
Frontotemporal Dementia (FTD): Carrying the C9ORF72 Gene Mutation
01:37
ALS & Frontotemporal Dementia (FTD): Daniel Barvin’s Personal Connection
01:14
Short #2: A Dire Unmet Need in Neurodegenerative Diseases
01:20
Short #4: Coya 302 Combination Biologic: The Aim to Stop ALS Disease Progression: POC Results
01:39
Short #3: Dysfunctional Tregs Apparent in Alzheimer's Disease (AD): COYA 301 in the Treatment of AD
01:10
Short #7: Coya's Treg Cell Therapy vs. CAR Treg Approaches
00:49
Short #6: Phase 2a Treg Cell Therapy Trial Results
02:04
Short #5: Phase 1 Treg Cell Therapy Study: Converting Bad Tregs Into Good Tregs
06:11
Short #1: Dr. Stanley Appel Interview - Coya's Novel Treatments for ALS and Alzheimer’s Disease
04:37
Coya CEO Howard Berman, Ph.D. - Appearance on Bloom TV
06:22
The Big Biz Show: Coya Pipeline Update
25:16
Howard Berman, Coya Therapeutics CEO Presents at Oppenheimer Rare & Orphan Disease Summit
02:38
Coya Mike Henson Interview with Dr Berman
03:23
Houston Methodist Immune cells hold promise in slowing down ALS
X
About
Coya Therapeutics is a platform cellular therapy company leveraging regulatory T cell (Treg) therapy for the treatment of neurodegenerative diseases.
Tags